These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 24678299)

  • 1. Biomarker-based diagnosis of mild cognitive impairment due to Alzheimer's disease: how and what to tell. A kickstart to an ethical discussion.
    Porteri C; Frisoni GB
    Front Aging Neurosci; 2014; 6():41. PubMed ID: 24678299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The biomarker-based diagnosis of Alzheimer's disease. 1-ethical and societal issues.
    Porteri C; Albanese E; Scerri C; Carrillo MC; Snyder HM; Martensson B; Baker M; Giacobini E; Boccardi M; Winblad B; Frisoni GB; Hurst S;
    Neurobiol Aging; 2017 Apr; 52():132-140. PubMed ID: 28317644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of the Ethical Issues of a Biomarker-Based Diagnoses in the Early Stage of Alzheimer's Disease.
    Vanderschaeghe G; Dierickx K; Vandenberghe R
    J Bioeth Inq; 2018 Jun; 15(2):219-230. PubMed ID: 29532386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and management of Alzheimer's disease: past, present and future ethical issues.
    Gauthier S; Leuzy A; Racine E; Rosa-Neto P
    Prog Neurobiol; 2013 Nov; 110():102-13. PubMed ID: 23578568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker-Based Risk Prediction of Alzheimer's Disease Dementia in Mild Cognitive Impairment: Psychosocial, Ethical, and Legal Aspects.
    Rostamzadeh A; Schwegler C; Gil-Navarro S; Rosende-Roca M; Romotzky V; Ortega G; Canabate P; Moreno M; Schmitz-Luhn B; Boada M; Jessen F; Woopen C
    J Alzheimers Dis; 2021; 80(2):601-617. PubMed ID: 33554900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethical Arguments Concerning the Use of Alzheimer's Disease Biomarkers in Individuals with No or Mild Cognitive Impairment: A Systematic Review and Framework for Discussion.
    Smedinga M; Tromp K; Schermer MHN; Richard E
    J Alzheimers Dis; 2018; 66(4):1309-1322. PubMed ID: 30507575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.
    Cavedo E; Lista S; Khachaturian Z; Aisen P; Amouyel P; Herholz K; Jack CR; Sperling R; Cummings J; Blennow K; O'Bryant S; Frisoni GB; Khachaturian A; Kivipelto M; Klunk W; Broich K; Andrieu S; de Schotten MT; Mangin JF; Lammertsma AA; Johnson K; Teipel S; Drzezga A; Bokde A; Colliot O; Bakardjian H; Zetterberg H; Dubois B; Vellas B; Schneider LS; Hampel H
    J Prev Alzheimers Dis; 2014 Dec; 1(3):181-202. PubMed ID: 26478889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment.
    Frederiksen KS; Nielsen TR; Winblad B; Schmidt R; Kramberger MG; Jones RW; Hort J; Grimmer T; Georges J; Frölich L; Engelborghs S; Dubois B; Waldemar G
    Eur J Neurol; 2021 Jul; 28(7):2147-2155. PubMed ID: 33368924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing for Alzheimer Disease Biomarkers and Disclosing Results Across the Disease Continuum.
    Largent EA; Grill JD; O'Brien K; Wolk D; Harkins K; Karlawish J
    Neurology; 2023 May; 100(21):1010-1019. PubMed ID: 36720642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.
    Vos SJ; Verhey F; Frölich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Morbelli S; Frisoni GB; Drzezga A; Didic M; van Berckel BN; Simmons A; Soininen H; Kłoszewska I; Mecocci P; Tsolaki M; Vellas B; Lovestone S; Muscio C; Herukka SK; Salmon E; Bastin C; Wallin A; Nordlund A; de Mendonça A; Silva D; Santana I; Lemos R; Engelborghs S; Van der Mussele S; ; Freund-Levi Y; Wallin ÅK; Hampel H; van der Flier W; Scheltens P; Visser PJ
    Brain; 2015 May; 138(Pt 5):1327-38. PubMed ID: 25693589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ethical considerations of biomarker use in neurodegenerative diseases--a case study of Alzheimer's disease.
    Prvulovic D; Hampel H
    Prog Neurobiol; 2011 Dec; 95(4):517-9. PubMed ID: 22137044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ethical considerations regarding the communication of diagnosis of prodromal Alzheimer's disease].
    Serrano CM; Sorokin P; Taragano F
    Vertex; 2014; 25(114):99-101. PubMed ID: 25153975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consent for the diagnosis of preclinical dementia states: A review.
    Hughes JC; Ingram TA; Jarvis A; Denton E; Lampshire Z; Wernham C
    Maturitas; 2017 Apr; 98():30-34. PubMed ID: 28274325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot.
    Hampel H; Lista S; Khachaturian ZS
    Alzheimers Dement; 2012 Jul; 8(4):312-36. PubMed ID: 22748938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Cedarbaum J; Green RC; Harvey D; Jack CR; Jagust W; Luthman J; Morris JC; Petersen RC; Saykin AJ; Shaw L; Shen L; Schwarz A; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2015 Jun; 11(6):e1-120. PubMed ID: 26073027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
    Albert MS; DeKosky ST; Dickson D; Dubois B; Feldman HH; Fox NC; Gamst A; Holtzman DM; Jagust WJ; Petersen RC; Snyder PJ; Carrillo MC; Thies B; Phelps CH
    Alzheimers Dement; 2011 May; 7(3):270-9. PubMed ID: 21514249
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.